Characteristics | Latent prostate cancer | Clinical prostate cancer | OR (95%CI) | P (lPCa vs cPCa) | ||
---|---|---|---|---|---|---|
Index tumor lesion | ||||||
Anterior | 12 | P = 0.670 | 63 | P = 0.221 | 0.993 (0.393–2.508) | P = 0.989 |
Posterior | 10 | 50 | ||||
Both anterior and posterior | 2 | 13 | – | |||
Peripheral zone | 19 | P = 0.002 | 82 | P < 0.001 | 0.774 (0.221–2.707) | P = 0.688 |
Transitional zone | 4 | 15 | ||||
Both peripheral zone transitional zone | 1 | 29 | – | |||
Apical 1/3 | 12 | P = 0.040 | 111 | P = 0.042 | – | |
Middle 1/3 | 16 | 111 | 0.749 (0.339–1.656) | P = 0.475 | ||
Basal 1/3 | 5 | 84 | 1.819 (0.617–5.365) | P = 0.278 | ||
Total tumor lesion | ||||||
Anterior | 23 | P = 0.435 | 206 | P = 0.843 | 1.247 (0.653–2.382) | P = 0.504 |
Posterior | 18 | 202 | ||||
Both anterior and posterior | 4 | 21 | - | |||
Peripheral zone | 36 | P < 0.001 | 350 | P < 0.001 | 0.754 (0.316–1.798) | P = 0.524 |
Transitional zone | 7 | 50 | ||||
Both peripheral zone transitional zone | 2 | 29 | – | |||
Apical 1/3 | 22 | P = 0.004 | 285 | P = 0.004 | ||
Middle 1/3 | 28 | 234 | 0.655 (0.364–1.177) | P = 0.157 | ||
Basal 1/3 | 8 | 165 | 1.616 (0.702–3.717) | P = 0.259 |